Suven Life Sciences Limited (IN:SUVEN)
:SUVEN
Want to see IN:SUVEN full AI Analyst Report?
Top Page
Suven Life Sciences Limited
(SUVEN)
Select Model
Select Model
Rating:48Neutral
Price Target:
₹266.00
▲(61.21% Upside)
Action:Reiterated
Date:05/21/26
The score is held down primarily by poor financial performance (persistent losses and ongoing cash burn). Technicals are a notable positive with strong upside momentum, but overbought indicators raise pullback risk. Valuation is also constrained because losses (negative P/E) and no stated dividend yield provide limited fundamental support.
Positive Factors
Contract R&D services business model
A fee-for-service, contract R&D model creates recurring, contract-backed revenue streams and multi-year customer relationships with pharma/biotech. This structural demand for outsourced chemistry and development work supports predictable utilization and revenue visibility over months to years.
Negative Factors
Persistent operating and net losses
Recurring operating and net losses indicate the core business is not generating earnings power. Over time this erodes equity, limits reinvestment capacity, and forces dependence on external capital, constraining strategic choices and long-term shareholder returns.
Read all positive and negative factors
Positive Factors
Negative Factors
Contract R&D services business model
A fee-for-service, contract R&D model creates recurring, contract-backed revenue streams and multi-year customer relationships with pharma/biotech. This structural demand for outsourced chemistry and development work supports predictable utilization and revenue visibility over months to years.
Read all positive factors
Suven Life Sciences Limited (SUVEN) vs. iShares MSCI India ETF (INDA)
Market Cap
₹70.90B
Dividend YieldN/A
Average Volume (3M)14.83K
Price to Earnings (P/E)―
Beta (1Y)1.74
Revenue Growth6.89%
EPS Growth-67.45%
CountryIN
Employees141
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-9.64
Shares Outstanding263,720,580
10 Day Avg. Volume16,308
30 Day Avg. Volume14,834
Financial Highlights & Ratios
PEG Ratio-0.17
Price to Book (P/B)5.07
Price to Sales (P/S)421.72
P/FCF Ratio-9.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Suven Life Sciences Limited Business Overview & Revenue Model
Company Description
Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and...
How the Company Makes Money
Suven Life Sciences primarily makes money by providing outsourced R&D and related services to other pharmaceutical and biotechnology companies. Its core revenue stream is contract-based work where customers pay for Suven’s capabilities in areas su...
Suven Life Sciences Limited Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
62
Positive
Cash Flow
9
Very Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 58.63M | 71.15M | 66.56M | 116.93M | 135.39M | 118.44M |
| Gross Profit | -151.32M | -419.28M | -276.33M | 108.69M | 129.74M | -137.31M |
| EBITDA | -2.06B | -2.85B | -1.55B | -992.78M | -1.11B | -1.17B |
| Net Income | -2.12B | -2.76B | -1.61B | -1.05B | -1.18B | -1.22B |
Balance Sheet | ||||||
| Total Assets | 3.37B | 6.24B | 1.35B | 2.85B | 3.89B | 1.08B |
| Cash, Cash Equivalents and Short-Term Investments | 2.59B | 5.18B | 600.05M | 2.40B | 2.31B | 504.36M |
| Total Debt | 0.00 | 166.94M | 0.00 | 7.10M | 16.05M | 32.09M |
| Total Liabilities | 561.36M | 328.14M | 251.97M | 148.62M | 135.91M | 118.89M |
| Stockholders Equity | 2.81B | 5.91B | 1.10B | 2.70B | 3.75B | 961.45M |
Cash Flow | ||||||
| Free Cash Flow | -1.06B | -3.03B | -1.86B | -1.15B | -1.06B | -1.47B |
| Operating Cash Flow | -1.03B | -2.98B | -1.48B | -1.15B | -1.03B | -1.28B |
| Investing Cash Flow | -2.02B | -4.66B | 1.49B | 944.36M | -2.61B | -222.29M |
| Financing Cash Flow | 3.00B | 7.57B | -7.10M | -10.54M | 3.96B | 1.46B |
Suven Life Sciences Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | ₹58.40B | 30.45 | ― | 0.13% | 9.68% | 6.17% | |
60 Neutral | ₹59.50B | 2.40 | ― | ― | 2518.32% | ― | |
57 Neutral | ₹34.82B | 13.21 | ― | 0.24% | 7.47% | 16.13% | |
57 Neutral | ₹28.55B | 67.80 | ― | 0.03% | 9.88% | -40.57% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | ₹70.90B | -10.86 | ― | ― | 6.89% | -67.45% |
* Healthcare Sector Average
IN:SUVEN
Suven Life Sciences Limited
268.40
53.10
24.66%
IN:AARTIDRUGS
Aarti Drugs Limited
380.95
-90.92
-19.27%
IN:GUFICBIO
Gufic Biosciences Limited
287.45
-92.90
-24.42%
IN:SPARC
Sun Pharma Advanced Research Co. Ltd.
180.45
17.95
11.05%
IN:SUPRIYA
Supriya Lifescience Limited
733.85
9.55
1.32%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.